Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sernova Corp (SVA.TO)

Sernova Corp (SVA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 68,982
  • Shares Outstanding, K 328,485
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,192 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.09
  • Most Recent Earnings $-0.02 on 03/14/25
  • Next Earnings Date 06/13/25
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +3,330,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1750 +22.86%
on 04/15/25
0.2300 -6.52%
on 05/14/25
+0.0450 (+26.47%)
since 04/14/25
3-Month
0.1500 +43.33%
on 03/31/25
0.2300 -6.52%
on 05/14/25
+0.0150 (+7.50%)
since 02/14/25
52-Week
0.1500 +43.33%
on 03/31/25
0.4000 -46.25%
on 06/03/24
-0.1050 (-32.81%)
since 05/14/24

Most Recent Stories

More News
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

/CNW/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to...

SVA.TO : 0.2150 (+2.38%)
SVA : 6.47 (-0.31%)
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouchâ„¢ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

/CNW/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's...

SVA.TO : 0.2150 (+2.38%)
SVA : 6.47 (-0.31%)
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)
Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

SVA.TO : 0.2150 (+2.38%)
SEOVF : 0.1553 (+6.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the...

See More

Key Turning Points

3rd Resistance Point 0.2400
2nd Resistance Point 0.2350
1st Resistance Point 0.2250
Last Price 0.2150
1st Support Level 0.2100
2nd Support Level 0.2050
3rd Support Level 0.1950

See More

52-Week High 0.4000
Fibonacci 61.8% 0.3045
Fibonacci 50% 0.2750
Fibonacci 38.2% 0.2455
Last Price 0.2150
52-Week Low 0.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar